Thromboembolic and bleeding complications following St. Jude Medical valve replacement: results of the German Experience With Low-Intensity Anticoagulation Study
- PMID: 15653962
- DOI: 10.1378/chest.127.1.53
Thromboembolic and bleeding complications following St. Jude Medical valve replacement: results of the German Experience With Low-Intensity Anticoagulation Study
Abstract
Study objectives: Due to their inherent thrombogenicity, mechanical cardiac valves necessitate lifelong oral anticoagulation. Less intensive oral anticoagulation than recommended earlier might result in a lower incidence of bleeding complications without increasing the embolic hazard significantly.
Design: Comparison of three different intensities of oral anticoagulation in a prospective, randomized multicenter design. Three months after valve replacement, patients were randomly assigned to stratum A, international normalized ratio (INR) 3.0 to 4.5; stratum B, INR 2.5 to 4.0; or stratum C, INR 2.0 to 3.5.
Patients: Data from 2,735 patients following aortic valve replacement (AVR; n = 2,024), mitral valve replacement (MVR; n = 553), and combined AVR and MVR (n = 158) with the St. Jude Medical (SJM) valve (St. Jude Medical; St. Paul, MN) between July 1993 and May 1999 were analyzed, covering a total follow-up period of 6,801 patient-years. All complications were registered prospectively.
Measurements and results: Fifty-one thromboembolic events (TEs) were documented, resulting in a linearized incidence of 0.75 TEs per 100 patient-years, 22 of which were minor (0.32% per patient-year), 10 were moderate (0.15% per patient-year), and 19 were severe (0.28% per patient-year). Thromboembolism following AVR was significantly lower than after MVR (0.53% per patient-year vs 1.64% per patient-year). Patients reported 1,687 bleeding complications (24.8% per patient-year). The vast majority of bleeding complications (n = 1,509; 22.2% per patient-year) were classified as minor, 140 were classified as moderate (2.06% per patient-year), and 38 were classified as severe (0.56% per patient-year). The clinically relevant incidences of moderate and severe TEs and bleeding complications were not significantly different between the three prespecified INR strata.
Conclusions: The intention-to-treat analysis of the results of the German Experience With Low Intensity Anticoagulation study leads to the unexpected result that despite a sophisticated reporting system, the incidence of moderate and severe TE and bleeding complications was comparably low in all INR strata and more or less within the so-called background incidence reported for an age-related "normal" population. This study supports reexamination of the intensity of anticoagulation in patients with the SJM valve.
Similar articles
-
Lower intensity anticoagulation therapy results in lower complication rates with the St. Jude Medical prosthesis.J Thorac Cardiovasc Surg. 1994 Apr;107(4):1136-45. J Thorac Cardiovasc Surg. 1994. PMID: 8159036
-
Thrombo-embolic and bleeding complications in patients with mechanical valve replacements--a prospective observational study.S Afr Med J. 2006 Aug;96(8):710-3. S Afr Med J. 2006. PMID: 17019493
-
INR self-management permits lower anticoagulation levels after mechanical heart valve replacement.Circulation. 2003 Sep 9;108 Suppl 1:II75-8. doi: 10.1161/01.cir.0000089185.80318.3f. Circulation. 2003. PMID: 12970212 Clinical Trial.
-
[Inhibition of thrombocyte aggregation after heart valve replacement].Z Kardiol. 1998;87 Suppl 4:46-55. Z Kardiol. 1998. PMID: 9857467 Review. German.
-
Mechanical heart valve patients can manage oral anticoagulant therapy themselves.Eur J Cardiothorac Surg. 2003 Mar;23(3):292-8. doi: 10.1016/s1010-7940(02)00817-5. Eur J Cardiothorac Surg. 2003. PMID: 12614796 Review.
Cited by
-
Flow dynamics of surgical and transcatheter aortic valves: Past to present.JTCVS Open. 2022 Jan 24;9:43-56. doi: 10.1016/j.xjon.2022.01.017. eCollection 2022 Mar. JTCVS Open. 2022. PMID: 36003460 Free PMC article.
-
2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.Circulation. 2014 Dec 2;130(23):e199-267. doi: 10.1161/CIR.0000000000000041. Epub 2014 Mar 28. Circulation. 2014. PMID: 24682347 Free PMC article. No abstract available.
-
Natural biomaterials in the management of the aortic valve pathology. Biomedical and clinical aspects: A review.Biomol Biomed. 2025 Jan 14;25(2):338-345. doi: 10.17305/bb.2024.11009. Biomol Biomed. 2025. PMID: 39319869 Free PMC article. Review.
-
Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Chest. 2012 Feb;141(2 Suppl):e576S-e600S. doi: 10.1378/chest.11-2305. Chest. 2012. PMID: 22315272 Free PMC article.
-
Analysis of Anticoagulation Therapy and Anticoagulation-Related Outcomes Among Asian Patients After Mechanical Valve Replacement.JAMA Netw Open. 2022 Feb 1;5(2):e2146026. doi: 10.1001/jamanetworkopen.2021.46026. JAMA Netw Open. 2022. PMID: 35103794 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical